Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

589 ARTÍCULOS , VIENDO DEL 286 AL 300

The hippocampal sparing subtype of Alzheimer's disease assessed in neuropathology and in vivo tau positron emission tomography: a systematic review

Ferreira D, Mohanty R, Murray ME, Nordberg A, Kantarci K, Westman E.

Acta Neuropathol Commun. 2022 Nov 14;10(1):166. doi: 10.1186/s40478-022-01471-z.

Alzheimer's Disease: Treatment Strategies and Their Limitations

Passeri E, Elkhoury K, Morsink M, Broersen K, Linder M, Tamayol A, Malaplate C, Yen FT, Arab-Tehrany E.

Int J Mol Sci. 2022 Nov 12;23(22):13954. doi: 10.3390/ijms232213954.

Efficacy and safety of blood derivatives therapy in Alzheimer's disease: a systematic review and meta-analysis

Fei Z, Pan B, Pei R, Chen Z, Du X, Cao H, Li C.

Syst Rev. 2022 Nov 29;11(1):256. doi: 10.1186/s13643-022-02115-y.

Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer's disease

Bateman RJ, Cummings J, Schobel S, Salloway S, Vellas B, Boada M, Black SE, Blennow K, Fontoura P, Klein G, Assunção SS, Smith J, Doody RS.

Alzheimers Res Ther. 2022 Nov 29;14(1):178. doi: 10.1186/s13195-022-01110-8.

Benefit and safety of antibiotics for Alzheimer's disease: Protocol for a systematic review and meta-analysis

Gao L, Shuai Y, Wen L, Zhang H, Zhang Y, Zhang X.

Medicine (Baltimore). 2022 Nov 25;101(47):e31637. doi: 10.1097/MD.0000000000031637.

Lecanemab for Alzheimer's disease: tempering hype and hope

The Lancet.

Lancet. 2022 Dec 3;400(10367):1899. doi: 10.1016/S0140-6736(22)02480-1.

The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer's disease

Du H, Meng X, Yao Y, Xu J.

Front Endocrinol (Lausanne). 2022 Nov 17;13:1033479. doi: 10.3389/fendo.2022.1033479. eCollection 2022.

Research Progress of Targeting Neuro-Immune Inflammation in the Treatment of Alzheimer's Disease

Chen H, Deng C, Meng Z, Meng S.

Front Biosci (Landmark Ed). 2022 Nov 25;27(11):312. doi: 10.31083/j.fbl2711312.

Natural Carotenoids as Neuroprotective Agents for Alzheimer's Disease: An Evidence-Based Comprehensive Review

Batool Z, Chen JH, Gao Y, Lu LW, Xu H, Liu B, Wang M, Chen F.

J Agric Food Chem. 2022 Dec 21;70(50):15631-15646. doi: 10.1021/acs.jafc.2c06206. Epub 2022 Dec 8.

Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer's disease

Dhadda S, Kanekiyo M, Li D, Swanson CJ, Irizarry M, Berry S, Kramer LD, Berry DA.

Alzheimers Res Ther. 2022 Dec 9;14(1):182. doi: 10.1186/s13195-022-01129-x.

Synthetic, Cell-Derived, Brain-Derived, and Recombinant β-Amyloid: Modelling Alzheimer's Disease for Research and Drug Development

Varshavskaya KB, Mitkevich VA, Makarov AA, Barykin EP.

Int J Mol Sci. 2022 Nov 30;23(23):15036. doi: 10.3390/ijms232315036.

Disease-Modifying Activity of Huperzine A on Alzheimer's Disease: Evidence from Preclinical Studies on Rodent Models

Yan YP, Chen JY, Lu JH.

Int J Mol Sci. 2022 Dec 3;23(23):15238. doi: 10.3390/ijms232315238.

Lecanemab for Alzheimer's disease

Walsh S, Merrick R, Richard E, Nurock S, Brayne C.

BMJ. 2022 Dec 19;379:o3010. doi: 10.1136/bmj.o3010.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias